To rule out the possibility that the anti‐tumor effects of this treatment regimen were specific to immunosuppressed mice, or either species or xenograft specific, we evaluated efficacy of the RGD4C/AAVP‐Grp78‐HSVtk on a standard mouse GBM model. The gene discussed is HSPA5; the disease is neoplasm.